Tan Le

Array ( [id] => 17168895 [patent_doc_number] => 20210322565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => CONJUGATE MOLECULE [patent_app_type] => utility [patent_app_number] => 17/340767 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17340767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398184 [patent_doc_number] => 20220040274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => METHOD FOR BLOCKING ANTIBODY ADMINISTRATION IN TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 17/327733 [patent_app_country] => US [patent_app_date] => 2021-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214479 [patent_doc_number] => 20210347816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => METHOD FOR AFFINITY PURIFICATION [patent_app_type] => utility [patent_app_number] => 17/239195 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769455 [patent_doc_number] => 20230364219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => SARS COV-2 SPIKE PROTEIN CONSTRUCT [patent_app_type] => utility [patent_app_number] => 17/918676 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18346691 [patent_doc_number] => 20230134801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => MHC RESTRICTED IMMUNOGENIC TELOMERASE REVERSE TRANSCRIPTASE -SPECIFIC PEPTIDES, THEIR COMPLEX CONJUGATES, AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/995703 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492647 [patent_doc_number] => 12534510 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Peptide-receptive MHC-I complex compositions and methods [patent_app_type] => utility [patent_app_number] => 17/233407 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 69 [patent_no_of_words] => 14657 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17008537 [patent_doc_number] => 20210239698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => IDENTIFICATION OF LIGANDS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/231689 [patent_app_country] => US [patent_app_date] => 2021-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18642403 [patent_doc_number] => 11766456 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Method for culturing natural killer cells using T cells [patent_app_type] => utility [patent_app_number] => 17/220865 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 18 [patent_no_of_words] => 8909 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389919 [patent_doc_number] => 20230158137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => CORONAVIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 17/995299 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977667 [patent_doc_number] => 20210221904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND HIV ANTIGENIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/301118 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077772 [patent_doc_number] => 12351825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Soluble antibody complexes for T cell or NK cell activation and expansion [patent_app_type] => utility [patent_app_number] => 17/191830 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 0 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18265289 [patent_doc_number] => 20230086531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => METHODS OF MANUFACTURING ACTIVATED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 17/909286 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -196 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17909286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399565 [patent_doc_number] => 20220041655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 17/178525 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18284528 [patent_doc_number] => 20230100000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens [patent_app_type] => utility [patent_app_number] => 17/797419 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258513 [patent_doc_number] => 20210371498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => MHC CLASS I COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/141096 [patent_app_country] => US [patent_app_date] => 2021-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17141096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915821 [patent_doc_number] => 20210188913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES [patent_app_type] => utility [patent_app_number] => 17/130192 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839560 [patent_doc_number] => 20210147572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/247767 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -169 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17247767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913936 [patent_doc_number] => 20210187028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => POLYCLONAL GAMMA DELTA T CELLS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/127627 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091391 [patent_doc_number] => 20220409732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => PEPTIDE-MHC II PROTEIN CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/780158 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19195286 [patent_doc_number] => 11992504 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-28 [patent_title] => Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment [patent_app_type] => utility [patent_app_number] => 16/953879 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 13 [patent_no_of_words] => 11094 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953879 [rel_patent_id] =>[rel_patent_doc_number] =>)